Matrix metalloproteinase inhibitor, doxycycline and progression of calcific aortic valve disease in hyperlipidemic mice

Jae-Joon Jung, PhD^{1,2*}, Mahmoud Razavian, PhD^{1,2*}, Hye-Yeong Kim^{1,2}, PhD, Yunpeng Ye, PhD^{1,2}, Reza Golestani, MD, PhD^{1,2}, Jakub Toczek, PhD^{1,2}, Jiasheng Zhang, MD^{1,2}, Mehran M. Sadeghi, MD^{1,2}

¹ Section of Cardiovascular Medicine and Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, United States. ² VA Connecticut Healthcare System, West Haven, CT, United States.

Supplemental Figure

Doxycycline and aortic valve MMP expression in CAVD. GAPDH-normalized MMP-9 (A) and MMP-12 (B) expression assessed by quantitative RT-PCR in aortic valve tissues of control and doxycycline-treated mice on high fat diet. n = 4 in each group.

